Adjuvant chemotherapy for colorectal cancer

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Colorectal cancer is a leading cause of cancer-related mortality globally.
• Survival rates for colorectal cancer have seen minimal improvement despite surgical advancements.
• Current prognostic markers lack superiority over traditional staging systems for predicting outcomes.

Purpose of the Study:

• To evaluate the role of adjuvant chemotherapy in colorectal cancer management.
• To determine the efficacy of immunomodulators, such as levamisole, in adjuvant chemotherapy regimens.
• To identify predictive markers for patient selection in adjuvant chemotherapy for colorectal cancer.

Main Methods:

• Review of prospective studies on adjuvant chemotherapy in colorectal cancer.
• Analysis of prognostic marker utility in predicting treatment response.
• Exploration of the potential benefit of adjuvant chemotherapy in Dukes' stage B colorectal cancer.

Main Results:

• Adjuvant chemotherapy has demonstrated clear benefits for patients with Dukes' stage C colorectal cancer.
• The role of adjuvant chemotherapy in Dukes' stage B colorectal cancer warrants further investigation.
• Existing prognostic markers do not adequately predict response to chemotherapy.

Conclusions:

• Further research, including large randomized trials, is essential to clarify the optimal use of adjuvant chemotherapy.
• Identifying specific patient subgroups who benefit most from adjuvant chemotherapy is crucial.
• Standardization of surgical and pathological assessment methods is recommended to improve patient outcomes.